• <em>Mitohormesis</em>: a key driver of the therapy resistance in cancer cells
• A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES
• A rare case of spontaneous hemoperitoneum in a bone marrow transplant recipient on VV-ECMO
• A rare case report of hemophagocytic lymphohistiocytosis secondary to pure eythroid leukemia in a person living with HIV
• A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?
• Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia
• AML, myelodysplasia related, with STAG2 and SRSF2 comutations with myelocyte arrest
• Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice
• Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial
• Cardiac Events after Allo-HCT in Patients with Acute Myeloid Leukemia. Study Conducted con Behalf of the GETH-TC
• CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target
• Cd39 and P2rx7-Wnt signaling enhance blast pathogenicity in an experimental model of acute myeloid leukemia
• Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis
• Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single-center retrospective analysis
• Clinical and Microbiological Characteristics of Febrile Neutropenia During Induction Chemotherapy in Adults With Acute Leukemia
• Co-occurrence of hydatid cyst liver with acute myeloid leukaemia: A rare case report
• Comparative analysis of BCR::ABL1 p210 mRNA transcript quantification and ratio to ABL1 control gene converted to the International Scale by chip digital PCR and droplet digital PCR for monitoring patients with chronic myeloid leukemia
• Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7 + 3 plus midostaurin induction for FLT-3 acute myelogenous leukemia
• Construction and validation of a SASP-related prognostic signature in patients with acute myeloid leukaemia
• Design and synthesis of 7-azaindole derivatives as potent CDK8 inhibitors for the treatment of acute myeloid leukemia
• Diagnostic value of procalcitonin in infections in patients with malignant hematologic diseases
• Dynamic relapse prediction by peripheral blood WT1mRNA after allogeneic hematopoietic cell transplantation for myeloid neoplasms
• Effects of different conditioning regimens on HLA-mismatched microtransplantation and changes in fine immune indices in acute myeloid leukaemia
• Emergence of clonal evolution with Philadelphia chromosome in acute myeloid leukemia after hypomethylation agents and BCL2 inhibitor treatment
• Emerging role of miR-520a in human diseases
• Enhanced depletion of MLL-fusion proteins in acute leukemia: potential for improved therapeutic outcomes
• Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment
• Enriching Anticancer Drug Pipeline with Potential Inhibitors of Cyclin-Dependent Kinase-8 Identified from Natural Products
• Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options
• Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment
• Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia
• Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies
• Exploration of the mechanism of fraxetin in treating acute myeloid leukemia based on network pharmacology and experimental verification
• Genome-wide CRISPR screening identifies critical role of phosphatase and tensin homologous (PTEN) in sensitivity of acute myeloid leukemia to chemotherapy
• Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients
• Genomic structural variants analysis in leukemia by a novel cytogenetic technique: Optical genome mapping
• Glycolysis and chemoresistance in acute myeloid leukemia
• Halogenated retinoid derivatives as dual RARalpha and RXRalpha modulators for treating acute promyelocytic leukemia cells
• Health-Related Quality of Life with Gilteritinib versus Placebo Post-Transplant for FLT3-ITD+ Acute Myeloid Leukemia
• Hematological Second Primary Malignancy in Pediatric Retinoblastoma: A Case Report and Systematic Review
• Hijacking T helper cells for AML progression
• How to customize common data models for rare diseases: an OMOP-based implementation and lessons learned
• How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms
• Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies
• Identification of epigenetic modifiers essential for growth and survival of AML1/ETO-positive leukemia
• Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties
• Identifying disease-modifying potential in myelofibrosis clinical trials
• IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells
• Immature erythroblasts in pleural effusion: an initial presentation of acute erythroid leukemia in a patient with a history of MDS
• Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection
• Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment
• Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT
• Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature
• Melphalan Dose in Combination with Fludarabine Affects GI Toxicity and GVHD after Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes
• MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response
• miR-149-3p Enhances Drug Sensitivity of AML Cells by Inhibiting Warburg Effect Through PI3K/AKT Pathway
• Molecular characteristics and oncogenic role of CHD family genes: a pan-cancer analysis based on bioinformatic and biological analysis
• Molecular pathophysiology of germline mutations in acute myeloid leukemia
• Multi-omics evaluation of the prognostic value and immune signature of FCN1 in pan-cancer and its relationship with proliferation and apoptosis in acute myeloid leukemia
• Mutual regulation between histone methyltransferase Suv39h1 and the Wnt/β-catenin signaling pathway promoted cell proliferation and inhibited apoptosis in bone marrow mesenchymal stem cells exposed to hydroquinone
• Myeloid sarcoma of the breast with synchronous early T-cell precursor acute lymphoblastic leukemia: A rare presentation
• Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations
• Novel insights and therapeutic approaches in secondary AML
• NPM1-mutated AML: how many diseases?
• Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
• Pan-cancer investigation of RFX family and associated genes identifies RFX8 as a therapeutic target in leukemia
• Phase separation of PML/RARalpha and BRD4 coassembled microspeckles governs transcriptional dysregulation in acute promyelocytic leukemia
• Post-transplantation cyclophosphamide and cyclosporine A versus methotrexate and cyclosporine A for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients
• Predictive Models for Long Term Survival of AML Patients Treated with Venetoclax and Azacitidine or 7+3 Based on Post Treatment Events and Responses: Retrospective Cohort Study
• Prognostic impact of enhanced CD96 expression on NK cells by TGF-β1 in AML
• Prognostic role of chemokine-related genes in acute myeloid leukemia
• Radiosynthesis of [(18)F]brequinar for in vivo PET imaging of hDHODH for potential studies of acute myeloid leukemia and cancers
• Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia
• Recent advances in AML with mutated NPM1
• Regulatory axis of circular RNA DTNB, microRNA-485-5p, and myeloid cell leukemia 1 attenuates inflammation and apoptosis in caerulein-treated AR42J cells
• Revealing of TLR-9 gene polymorphisms by qPCR HRM technique and their influence on TLR-9 serum level in acute myeloid leukemia patients: Case-control study
• RNA binding protein-directed control of leukemic stem cell evolution and function
• Salvage hematopoietic cell transplantation for children with acute myeloid leukemia relapsed after first transplantation: a Japanese national registry study
• Second chances for secondary AML
• Similarities and differences of bone marrow and peripheral blood samples from acute myeloid leukemia patients in terms of cellular heterogeneity and ex-vivo drug sensitivity
• Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia
• STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells
• Successful treatment of refractory donor-specific-human leukocyte antigen-antibody-induced primary graft-failure with daratumumab: A case report
• Synthetic Data Generation in Hematology - Paving the Way for OMOP and FHIR Integration
• Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia
• Targeted lipidomics-based study of radiation-induced metabolite profiles changes in plasma of total body irradiation cases
• The changing landscape of geriatric care in acute myeloid leukemia: a 5-year analysis of inpatient mortality predictors, trends in mortality, and chemotherapy use
• The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells
• Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia
• Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report
• Treatment of Acute Myeloid Leukemia in the Community Setting
• Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT
• Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis
• Unveiling the Tempest: Dermal Plasmacytoid Dendritic Cell Proliferation as the Harbinger of Acute Myeloid Leukemia
• Use of extracellular vesicle microRNA profiles in patients with acute myeloid leukemia for the identification of novel biomarkers
• Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms
• Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia
• Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation
• Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification
• Young (<35 years) haploidentical versus old (35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on beha